ArticleTranslational andrology and urology2025
Age-related variations in thyroid function hormones indicate the risk of prostate cancer: evidence from a nationally representative dataset.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk of prostate cancer (PCa) is closely related to age and influenced by endocrine hormone imbalances. The study aimed to discuss the association between thyroid function hormone variations across different age groups and PCa as well as prostate-specific antigen (PSA) levels. Methods: We analyzed data from two National Health and Nutrition Examination Survey (NHANES) cycles (2007-2008, 2009-2010). Serum thyroid function tests were conducted using immunoenzymatic assays. PCa was identified through self-reported diagnosis, and highly-probable PCa was identified by elevated PSA (>10 ng/mL or 4-10 ng/mL with a PSA ratio <10%). Weighted multivariable logistic regression assessed the relationship between thyroid hormone levels and the risk of PCa and highly-probable PCa. Results: Among 2,169 participants, the prevalence of PCa was 5.35%, higher in those aged ≥65 years (12.13%) compared to those <65 years (1.52%). Elevated total triiodothyronine (TT3) and free triiodothyronine (FT3) were significantly associated with increased PCa risk in older adults [TT3: odds ratio (OR) =1.481, P<0.001; FT3: OR =1.452, P<0.001]. Among those without PCa, elevated total thyroxine (TT4) and free thyroxine (FT4) were associated with higher highly-probable PCa, with TT4 indicating early risk in individuals younger than 65 years, and FT4 in those 65 years or older. Higher TSH levels were associated with increased PSA ratio, while TT3 and FT3 showed stronger inverse age-dependent associations with total and free PSA levels. FT4 was only negatively associated with PSA ratio in older adults. Conclusions: Thyroid function hormone levels were associated with PCa risk in older adults and also indicated an increased early risk of PCa in younger adults, as reflected by PSA markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.